S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
10 Best Airline Stocks to Buy
Graphite Shortage Could Derail the $7 Trillion EV Transition (Ad)
Stock market today: Global shares trade mixed following technology selloff on Wall Street
What is a Growth Stock Mutual Fund?
Graphite Shortage Could Derail the $7 Trillion EV Transition (Ad)
Ollie’s Bargain Outlet Goes On Sale 
Will MicroVision Maintain Its Momentum After the Short Squeeze?
Graphite Shortage Could Derail the $7 Trillion EV Transition (Ad)
Apple Partnership Strengthens Unity Software's Investment Appeal
Campbell Soup Company Leads Staples Stocks Into The Buy Zone
S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
10 Best Airline Stocks to Buy
Graphite Shortage Could Derail the $7 Trillion EV Transition (Ad)
Stock market today: Global shares trade mixed following technology selloff on Wall Street
What is a Growth Stock Mutual Fund?
Graphite Shortage Could Derail the $7 Trillion EV Transition (Ad)
Ollie’s Bargain Outlet Goes On Sale 
Will MicroVision Maintain Its Momentum After the Short Squeeze?
Graphite Shortage Could Derail the $7 Trillion EV Transition (Ad)
Apple Partnership Strengthens Unity Software's Investment Appeal
Campbell Soup Company Leads Staples Stocks Into The Buy Zone
S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
10 Best Airline Stocks to Buy
Graphite Shortage Could Derail the $7 Trillion EV Transition (Ad)
Stock market today: Global shares trade mixed following technology selloff on Wall Street
What is a Growth Stock Mutual Fund?
Graphite Shortage Could Derail the $7 Trillion EV Transition (Ad)
Ollie’s Bargain Outlet Goes On Sale 
Will MicroVision Maintain Its Momentum After the Short Squeeze?
Graphite Shortage Could Derail the $7 Trillion EV Transition (Ad)
Apple Partnership Strengthens Unity Software's Investment Appeal
Campbell Soup Company Leads Staples Stocks Into The Buy Zone
S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
10 Best Airline Stocks to Buy
Graphite Shortage Could Derail the $7 Trillion EV Transition (Ad)
Stock market today: Global shares trade mixed following technology selloff on Wall Street
What is a Growth Stock Mutual Fund?
Graphite Shortage Could Derail the $7 Trillion EV Transition (Ad)
Ollie’s Bargain Outlet Goes On Sale 
Will MicroVision Maintain Its Momentum After the Short Squeeze?
Graphite Shortage Could Derail the $7 Trillion EV Transition (Ad)
Apple Partnership Strengthens Unity Software's Investment Appeal
Campbell Soup Company Leads Staples Stocks Into The Buy Zone
NASDAQ:INCY

Incyte (INCY) Stock Forecast, Price & News

$61.39
-0.32 (-0.52%)
(As of 06/7/2023 ET)
Compare
Today's Range
$61.01
$61.90
50-Day Range
$61.39
$75.51
52-Week Range
$60.71
$86.29
Volume
1.64 million shs
Average Volume
1.61 million shs
Market Capitalization
$13.70 billion
P/E Ratio
42.34
Dividend Yield
N/A
Price Target
$81.50

Incyte MarketRank™ Forecast

Analyst Rating
Hold
2.27 Rating Score
Upside/​Downside
32.8% Upside
$81.50 Price Target
Short Interest
Healthy
3.19% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.42
Upright™ Environmental Score
News Sentiment
0.51mentions of Incyte in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
40.14%
From $2.89 to $4.05 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.02 out of 5 stars

Medical Sector

16th out of 981 stocks

Biotechnology Industry

1st out of 18 stocks


INCY stock logo

About Incyte (NASDAQ:INCY) Stock

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States, Europe, Japan, and internationally. The company offers JAKAFI (ruxolitinib), for the treatment of adults with intermediate or high-risk myelofibrosis; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include axatilimab, an anti-CSF-1R monoclonal antibody being developed as a therapy for patients with chronic GVHD as well as in additional immune-mediated diseases; and parsaclisib, a PI3Kd inhibitor which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. It also develops retifanlimab, is in Phase III clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer, and Fast Track designation for the treatment of metastatic MSI-H or DNA mismatch repair (dMMR) endometrial cancer; and INCB99280 and INCB99318 currently under Phase I for the treatment solid tumors. It has collaboration out- license agreements with Novartis, Lilly, Innovent, InnoCare, Maruho, and CMS Aesthetics Limited; and in- license agreements with Agenus, Merus, MacroGenics, Syros, MorphoSys, and Syndax. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Receive INCY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Incyte and its competitors with MarketBeat's FREE daily newsletter.

INCY Stock News Headlines

New "Mined in America" Lithium Opportunities?
The average electric vehicle needs 138 pounds of lithium carbonate for its battery components. But China currently controls the entire lithium supply chain.
Incyte Corp INCY Stock Quote
Guru Fundamental Report for INCY
New "Mined in America" Lithium Opportunities?
The average electric vehicle needs 138 pounds of lithium carbonate for its battery components. But China currently controls the entire lithium supply chain.
Incyte (NASDAQ:INCY) PT Lowered to $70.00
Incyte (NASDAQ:INCY) Price Target Cut to $82.00
Incyte (NASDAQ:INCY) PT Lowered to $73.00
StockNews.com Downgrades Incyte (NASDAQ:INCY) to Buy
Bank of America Lowers Incyte (NASDAQ:INCY) to Neutral
Incyte (NASDAQ:INCY) Shares Gap Down to $75.34
See More Headlines

INCY Price History

INCY Company Calendar

Last Earnings
2/07/2023
Today
6/07/2023
Next Earnings (Estimated)
8/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Commercial physical research
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:INCY
CUSIP
45337C10
Employees
2,324
Year Founded
1991

Price Target and Rating

Average Stock Price Forecast
$81.50
High Stock Price Forecast
$100.00
Low Stock Price Forecast
$61.00
Forecasted Upside/Downside
+32.8%
Consensus Rating
Hold
Rating Score (0-4)
2.27
Research Coverage
15 Analysts

Profitability

Net Income
$340.66 million
Pretax Margin
14.71%

Debt

Sales & Book Value

Annual Sales
$3.39 billion
Cash Flow
$2.40 per share
Book Value
$19.64 per share

Miscellaneous

Free Float
184,048,000
Market Cap
$13.70 billion
Optionable
Optionable
Beta
0.72

Social Links


Key Executives

  • Herve HoppenotHerve Hoppenot
    Chairman, President & Chief Executive Officer
  • Christiana Stamoulis
    Chief Financial Officer & Executive Vice President
  • Steven H. SteinSteven H. Stein
    Chief Medical Officer & Executive Vice President
  • Dashyant DhanakDashyant Dhanak
    Chief Scientific Officer & Executive VP
  • Barry P FlannellyBarry P Flannelly
    EVP & General Manager-North America













INCY Stock - Frequently Asked Questions

Should I buy or sell Incyte stock right now?

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Incyte in the last year. There are currently 1 sell rating, 9 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" INCY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INCY, but not buy additional shares or sell existing shares.
View INCY analyst ratings
or view top-rated stocks.

What is Incyte's stock price forecast for 2023?

15 brokerages have issued 12 month price objectives for Incyte's stock. Their INCY share price forecasts range from $61.00 to $100.00. On average, they anticipate the company's share price to reach $81.50 in the next year. This suggests a possible upside of 32.8% from the stock's current price.
View analysts price targets for INCY
or view top-rated stocks among Wall Street analysts.

How have INCY shares performed in 2023?

Incyte's stock was trading at $80.32 at the beginning of the year. Since then, INCY shares have decreased by 23.6% and is now trading at $61.39.
View the best growth stocks for 2023 here
.

Are investors shorting Incyte?

Incyte saw a drop in short interest in May. As of May 15th, there was short interest totaling 7,010,000 shares, a drop of 5.9% from the April 30th total of 7,450,000 shares. Based on an average daily volume of 1,590,000 shares, the short-interest ratio is currently 4.4 days. Approximately 3.2% of the shares of the company are short sold.
View Incyte's Short Interest
.

When is Incyte's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 1st 2023.
View our INCY earnings forecast
.

How were Incyte's earnings last quarter?

Incyte Co. (NASDAQ:INCY) announced its quarterly earnings results on Tuesday, February, 7th. The biopharmaceutical company reported $0.62 earnings per share for the quarter, beating the consensus estimate of $0.59 by $0.03. The biopharmaceutical company earned $926.70 million during the quarter, compared to the consensus estimate of $880.25 million. Incyte had a trailing twelve-month return on equity of 9.99% and a net margin of 9.35%. The firm's revenue for the quarter was up 7.4% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.07) earnings per share.
Read the conference call transcript
.

What is Hervé Hoppenot's approval rating as Incyte's CEO?

22 employees have rated Incyte Chief Executive Officer Hervé Hoppenot on Glassdoor.com. Hervé Hoppenot has an approval rating of 80% among the company's employees.

What other stocks do shareholders of Incyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Incyte investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), (KITE) (KITE), Freeport-McMoRan (FCX) and NVIDIA (NVDA).

What is Incyte's stock symbol?

Incyte trades on the NASDAQ under the ticker symbol "INCY."

Who are Incyte's major shareholders?

Incyte's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Baker BROS. Advisors LP (16.22%), BlackRock Inc. (9.25%), Dodge & Cox (8.67%), State Street Corp (4.18%), Renaissance Technologies LLC (2.51%) and Geode Capital Management LLC (1.78%). Insiders that own company stock include Barry P Flannelly, Bros Advisors Lp Baker, Dashyant Dhanak, Herve Hoppenot, Jonathan Elliott Dickinson, Maria E Pasquale, Michael James Morrissey, Paul Trower, Paula J Swain, Steven H Stein, Thomas Tray, Vijay K Iyengar, Wendy L Dixon and Yao Wenqing.
View institutional ownership trends
.

How do I buy shares of Incyte?

Shares of INCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Incyte's stock price today?

One share of INCY stock can currently be purchased for approximately $61.39.

How much money does Incyte make?

Incyte (NASDAQ:INCY) has a market capitalization of $13.70 billion and generates $3.39 billion in revenue each year. The biopharmaceutical company earns $340.66 million in net income (profit) each year or $1.45 on an earnings per share basis.

How many employees does Incyte have?

The company employs 2,324 workers across the globe.

How can I contact Incyte?

Incyte's mailing address is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. The official website for the company is www.incyte.com. The biopharmaceutical company can be reached via phone at (302) 498-6700, via email at mbooth@incyte.com, or via fax at 302-425-2750.

This page (NASDAQ:INCY) was last updated on 6/8/2023 by MarketBeat.com Staff

My Account -